Literature DB >> 17803338

A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Philip Home, Adrian Bagust, Matthew Taylor, Philip Ambery, Samara Mendes da Costa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17803338     DOI： 10.2165/00019053-200725090-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  6 in total

1.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

2.  A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.

Authors:  Dominic P Tilden; Segundo Mariz; Gillies O'Bryan-Tear; Julia Bottomley; Alexander Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.

Authors:  Ronald B Goldberg; David M Kendall; Mark A Deeg; John B Buse; Anthony J Zagar; Jane A Pinaire; Meng H Tan; Mehmood A Khan; Alfonso T Perez; Scott J Jacober
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

4.  Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.

Authors:  Markolf Hanefeld; Nikolaus Marx; Andreas Pfützner; Werner Baurecht; Georg Lübben; Efstrathios Karagiannis; Ulf Stier; Thomas Forst
Journal:  J Am Coll Cardiol       Date:  2007-01-08       Impact factor: 24.094

5.  Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data.

Authors:  Adrian Bagust; Sophie Beale
Journal:  Health Econ       Date:  2005-03       Impact factor: 3.046

6.  Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).

Authors:  Philip Clarke; Alastair Gray; Rury Holman
Journal:  Med Decis Making       Date:  2002 Jul-Aug       Impact factor: 2.583
  6 in total
  1 in total

Review 1.  Rosiglitazone : a review of its use in type 2 diabetes mellitus.

Authors:  Emma D Deeks; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.